Anumana’s AI ECG Technology Recognized in CMS 2025 Rule, Expanding Cardiovascular Care

Anumana, a leading AI-driven health technology company, announced that the Centers for Medicare & Medicaid Services (CMS) has recognized its low ejection fraction (LEF) ECG-AI™ technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under APC 5734.…

Read MoreAnumana’s AI ECG Technology Recognized in CMS 2025 Rule, Expanding Cardiovascular Care

Genmab to Highlight Epcoritamab-bysp Development at 2024 ASH Annual Meeting

Genmab A/S (Nasdaq: GMAB) today announced that over 20 abstracts evaluating epcoritamab-bysp (EPKINLY®), a subcutaneously administered T-cell engaging bispecific antibody, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), taking place December 7-10, 2024,…

Read MoreGenmab to Highlight Epcoritamab-bysp Development at 2024 ASH Annual Meeting

Immunis Launches Preclinical Studies for Canine Muscle Atrophy Treatment

Immunis, Inc., a clinical-stage biotechnology company focused on developing innovative secretomes for age-related diseases and immune dysfunction, has launched non-terminal safety studies for canine muscle atrophy in collaboration with VetBio Partners, LLC. This follows the successful preclinical results of Immunis’…

Read MoreImmunis Launches Preclinical Studies for Canine Muscle Atrophy Treatment